

Financial Tear Sheet

Corporate Profile

We are a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

We aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders.

Stock Information

AXSM (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$3.23
Change (%)	0.00 (0.00%)
Volume	0
52 Week High	\$6.45
52 Week Low	\$2.05
Market Cap	\$82,835,712
Rolling EPS	-1.07
PE Ratio	0
Shares Outstanding	25,685,492



Data as of June 15, 2018 4:00 p.m. ET

Recent Headlines

June 5, 2018

Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder

May 29, 2018

Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting

May 22, 2018

Axsome Therapeutics to Present at the 2018 BIO International Convention

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
June 5, 2018	4
June 5, 2018	4
June 5, 2018	4
June 5, 2018	4